Recurrent Cutaneous T-cell lymphoma

Also known as: Recurrent T-Cell Lymphoma / Relapsed T-Cell Lymphoma / T-Cell Lymphoma Relapsed / T-cell lymphoma recurrent / T-cell lymphoma NOS recurrent

DrugDrug NameDrug Description
DB02546VorinostatVorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]
DrugDrug NamePhaseStatusCount
DB01234Dexamethasone0Terminated1
DB00059Pegaspargase0Terminated1
DB11945Avelumab2Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01073Fludarabine2Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB00877Sirolimus2Recruiting1
DB11581Venetoclax2Not Yet Recruiting1
DB06813Pralatrexate3Active Not Recruiting1